Caris Life Sciences, Inc. revenue by segment CAI

Caris Life Sciences, Inc. splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Molecular Profiling Services at $262.7 million, 95% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Sep 30, 2026
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Revenue
1,048
275
264
216
293
217
181
Molecular Profiling Services
1,008
+74.1%
share 96.2%
263
+26.6%
share 95.4%
252
+54.8%
share 95.7%
211
share 97.5%
282
share 96.3%
208
share 95.7%
163
share 89.8%
Pharma Research And Development Services
40
-42.5%
share 3.8%
13
+36.8%
share 4.6%
11
-38.0%
share 4.3%
5
share 2.5%
11
share 3.7%
9
share 4.3%
18
share 10.2%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Services-Medical Laboratories (SIC 8071)
Listed as
CAI (Nasdaq)
Fiscal year ends
December 31
Incorporated in
TX
Headquarters
Irving, TX
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
2019410

Other Services-Medical Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.